PHAT — Phathom Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1783183 ·
Last close
$9.82
Market Cap
$783.20M
52W High
$13.66
52W Low
$8.78
ADV30
1,368,140
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 58,301,000 | 46,305,000 | -15,477,000 | -30,369,000 | 305,120,000 | 180,904,000 | 642,075,000 |
| Dec 2025 | 57,584,000 | 49,936,000 | -5,928,000 | -21,148,000 | 259,149,000 | 129,972,000 | 697,318,000 |
| Sep 2025 | 49,504,000 | 43,314,000 | -15,271,000 | -29,973,000 | 240,289,000 | 135,156,000 | 662,823,000 |
| Jun 2025 | 39,503,000 | 34,465,000 | -59,924,000 | -75,810,000 | 250,220,000 | 149,569,000 | 656,054,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-97,492,000
Investing CF
$-272,000
Financing CF
$66,352,000
CapEx
$-272,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,514,627,000
Inventory
$6,508,000
Receivables
$80,724,000
ST Investments
—
EBIT TTM
$-91,458,000
Pretax Income TTM
$-157,300,000
Interest Exp TTM
$65,842,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$204,892,000
EBITDA
$-96,034,000
Free Cash Flow
$-77,528,624
Enterprise Value
$1,163,872,384
Total Cash
$180,904,000
Total Debt
$547,217,024
Shares Out
79,755,953
Trailing EPS
$-2.09
Book Value
$-4.24
ROE
—
ROA
-20.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 175,110,000 | -159,986,000 | -221,247,000 | 259,149,000 | 697,318,000 | — | -166,775,000 |
| Dec 2024 | 55,252,000 | -277,467,000 | -334,326,000 | 378,318,000 | 631,898,000 | — | -266,770,000 |
| Dec 2023 | 682,000 | -167,312,000 | -201,592,000 | 413,842,000 | 486,601,000 | — | -137,580,000 |
| Dec 2022 | 0 | -172,440,000 | -197,723,000 | 164,810,000 | 239,624,000 | — | -146,530,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.44
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $9.82 · call volume: 72 · put volume: 45
Expected Move to 2027-01-15:
±$5.85
(59.57%) —
implied range
$3.97 –
$15.67
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | $782.10M | $8.81 | — |
| CYRX | Cryoport, Inc. | $765.61M | $15.19 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $807.51M | $13.66 | — |
| ESPR | Esperion Therapeutics, Inc. | $809.16M | $3.14 | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $752.28M | $5.10 | — |
News headlines (Yahoo Finance, 1h cache)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-22 12:00 · Yahoo
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
2026-05-20 12:00 · Yahoo
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline
2026-05-05 10:12 · Yahoo
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks
2026-05-03 10:08 · Yahoo
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
2026-05-01 12:00 · Yahoo
Phathom Pharmaceuticals Q1 Earnings Call Highlights
2026-05-01 01:41 · Yahoo
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-01 00:48 · Yahoo
Phathom (PHAT) Q1 2026 Earnings Transcript
2026-04-30 21:16 · Yahoo
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
2026-04-30 12:30 · Yahoo
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-30 10:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.